Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL249358 | 0.83 | ALDH1A1 (0.43) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL93075 | 0.82 | ALDH1A1 (0.65) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL10882492 | 0.82 | ALDH1A1 (0.46) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL29588402 | 0.82 | ALDH1A1 (0.65) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL15919027 | 0.82 | ALOX15 (0.46) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL159093 | 0.81 | CASP1 (0.43) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL111964 | 0.81 | CASP1 (0.43) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL20149147 | 0.80 | TSHR (0.38) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL7609773 | 0.80 | TDP1 (0.39) | GAAALDH1A1USP2PKMHPGD | |
| SCHEMBL22303989 | 0.80 | ALDH1A1 (0.41) | GAAALDH1A1USP2PKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108346824-A | Nonaqueous electrolytic solution and nonaqueous electrolytic solution secondary battery | 索尼公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-101516948-B | Diamine chain extender compositions | ALBEMARLE CORP | 2012-08-15 | — | — | CN | disclosed |
| CN-101568566-B | Formulations for reaction injection molding and for spray systems | ALBEMARLE CORP | 2012-07-11 | — | — | CN | disclosed |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2011-05-12 | — | — | US | disclosed |
| US-7696246-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-04-13 | — | — | US | disclosed |
| US-20100069379-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED | 2010-03-18 | — | — | US | disclosed |
| CN-100384823-C | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2008-04-30 | — | — | CN | disclosed |
| CN-101029042-A | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-09-05 | — | — | CN | disclosed |
| CN-1262540-C | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2006-07-05 | — | — | CN | disclosed |
| CN-1775759-A | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2006-05-24 | — | — | CN | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
| CN-1382124-A | Bicyclic androgen and progesterone receptor modulating compounds and methods | LIGAND PHARM INC (US) | 2002-11-27 | — | — | CN | disclosed |
| EP-1212303-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016108-A2 | BICYCLIC ANDROGEN AND PROGESTERONE RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069379-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GAA 4834/4885ALDH1A1 2131/4885USP2 3856/4885 |
| US-20110112084-A9 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GAA 4834/4885ALDH1A1 2131/4885USP2 3856/4885 |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | GAA 4885/4885ALDH1A1 2798/4885USP2 2793/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GAA 4834/4885ALDH1A1 2131/4885USP2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.